Réf.HematoStat.net ; 2 (11) : V68 Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress. Robert A Ariëns and al. Res Pract Thromb Haemost. 2022 Jul 6;6(5):e12747. doi: 10.1002/rth2.12747.

Réf.HematoStat.net ; 2 (11) : V67 Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The […]

Réf.HematoStat.net ; 2 (11) : V66 Understanding COVID-19-associated coagulopathy. Ann-Katrin Wienkamp and al. Front Immunol. 2022 Aug 1;13:953129. doi: 10.3389/fimmu.2022.953129.

Réf.HematoStat.net ; 2 (11) : V65 Platelets in the NETworks interweaving inflammation and thrombosis  PMID: 35979369

Réf.HematoStat.net ; 2 (11) : V64 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Farge D and […]

Réf :HematoStat.net ; 2 (7) : V63 EORTC Quality of Life Group. International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic […]

Réf :HematoStat.net ; 2 (7) : V62 Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio […]

Réf :HematoStat.net ; 2 (7) : V60 Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, Martinez-Calle N, […]

Réf :HematoStat.net ; 2 (7) : V59 Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. Rigolin GM, Del Giudice I, […]

Réf :HematoStat.net ; 2 (7) : V58 Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, […]